We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+10.65%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.58B
AUM Growth
-$133M
Cap. Flow
-$75.4M
Cap. Flow %
-1.64%
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$102M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$50.7M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$48.4M
4
CGEM icon
Cullinan Oncology
CGEM
+$43.7M
5
AZN icon
AstraZeneca
AZN
+$32.7M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$58.7M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$47.9M
3
UNH icon
UnitedHealth
UNH
+$45M
4
CNC icon
Centene
CNC
+$43.8M
5
IMVT icon
Immunovant
IMVT
+$41.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.74%
2 Consumer Staples 1.75%
3 Industrials 0.62%
4 Financials 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
51
Madrigal Pharmaceuticals
MDGL
$11.9B
$30.2M 0.66%
258,500
+1,732
+0.7% +$202K
ASND icon
52
Ascendis Pharma A/S
ASND
$16.8B
$30.1M 0.66%
233,500
– –
MIRM icon
53
Mirum Pharmaceuticals
MIRM
$6.02B
$29.8M 0.65%
1,502,800
+6,275
+0.4% +$120K
EVH icon
54
Evolent Health
EVH
$444M
$29.2M 0.64%
+1,445,000
New +$27.5M
PRTA icon
55
Prothena Corp
PRTA
$468M
$29.1M 0.63%
1,156,900
+15,800
+1% +$297K
SWAV
56
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$28.7M 0.63%
220,000
– –
ACCD
57
DELISTED
Accolade Inc
ACCD
$28.4M 0.62%
625,000
+125,000
+25% +$6.02M
ACAD icon
58
Acadia Pharmaceuticals
ACAD
$5.06B
$27.8M 0.61%
1,076,200
-536,300
-33% -$23.6M
LUNG icon
59
Pulmonx
LUNG
$97.9M
$27.1M 0.59%
592,500
+92,500
+19% +$5.31M
SPRB
60
Spruce Biosciences
SPRB
$127M
$26.2M 0.57%
21,057
-690
-3% -$1.06M
ADPT icon
61
Adaptive Biotechnologies
ADPT
$4.05B
$26.2M 0.57%
650,000
+15,000
+2% +$812K
AMRN
62
Amarin Corp
AMRN
$298M
$26.1M 0.57%
209,750
– –
PPD
63
DELISTED
PPD, Inc. Common Stock
PPD
$25.5M 0.56%
675,000
+150,000
+29% +$5.38M
SRPT icon
64
Sarepta Therapeutics
SRPT
$1.81B
$24.5M 0.53%
328,750
– –
EPZM
65
DELISTED
Epizyme, Inc
EPZM
$24.4M 0.53%
2,802,954
+249,746
+10% +$2.58M
KYMR icon
66
Kymera Therapeutics
KYMR
$9.03B
$24.2M 0.53%
621,777
-92,088
-13% -$5.54M
NVCR icon
67
NovoCure
NVCR
$2.02B
$23.1M 0.5%
175,000
– –
XENT
68
DELISTED
Intersect ENT, Inc
XENT
$22.6M 0.49%
1,080,200
+380,200
+54% +$8.77M
COLL icon
69
Collegium Pharmaceutical
COLL
$882M
$21.8M 0.48%
920,000
-180,000
-16% -$4.28M
INSP icon
70
Inspire Medical Systems
INSP
$1.73B
$20.7M 0.45%
100,000
-113,350
-53% -$24.1M
ABCM
71
DELISTED
Abcam PLC
ABCM
$20.6M 0.45%
1,069,236
+144,236
+16% +$3.17M
OSH
72
DELISTED
Oak Street Health, Inc.
OSH
$20.4M 0.44%
375,000
– –
KURA icon
73
Kura Oncology
KURA
$874M
$20.1M 0.44%
710,035
+201,919
+40% +$6.39M
BMRN icon
74
BioMarin Pharmaceuticals
BMRN
$13.3B
$19.1M 0.42%
253,500
– –
RCKT icon
75
Rocket Pharmaceuticals
RCKT
$397M
$17.9M 0.39%
403,070
+2,700
+0.7% +$148K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rock Springs Capital Management held 172 positions worth $4.58B, down 2.8% from $4.72B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q1 2021 filing shows 18 new, 60 increased, 32 reduced and 21 closed positions. Its largest new stake was Immunocore: 2,292,285 shares worth $97.6M. The largest sale was Neurocrine Biosciences, an estimated $58.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2021 buy was Immunocore: 2,292,285 shares worth $97.6M.
  • Rock Springs Capital Management added most to Five Prime Therapeutics, Inc. in Q1 2021, an estimated $48.4M increase.
  • Rock Springs Capital Management's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $58.7M.
  • Rock Springs Capital Management fully exited Alexion Pharmaceuticals in Q1 2021, selling an estimated $47.9M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.58B portfolio in Q1 2021.
  • Rock Springs Capital Management opened 18 new positions and closed 21 in Q1 2021.
  • Rock Springs Capital Management's portfolio value fell 2.8% quarter-over-quarter to $4.58B.

Based on Rock Springs Capital Management's 13F filing for Q1 2021, filed 17 May 2021.